Diagnostring

Diagnostring has developed the first indigenous genomic diagnostic test to identify risk of recurrence and patient survival (and potentially treatment predictive) for cancer. Our first in vitro diagnostic (IVD) test will be available under the trade name MarbaLife^TM which predicts recurrence and survival in hormone/estrogen-receptor (ER) positive breast cancer patients. The test has successfully completed an early phase retrospective clinical validation in an Indian breast cancer cohort. We are seeking partners and investers to conduct further retrospective and prospective clinical validation. This is the first AI/ML-driven genomic test indigenously developed and has the potential to make global footprint. We extend invitation to join us and be part of the AI/ML-driven genomic healthcare revolution in India. Investors interested in MarbaLife^TM are encouraged to visit our product page and contact us.

About Us

Diagnostring Laboratories Limited Company, powered by the science of artificial intelligence and machine learning (AI/ML), is participating in India's 21st century genomic healthcare revolution. Diagnostring hopes to democratize genomic healthcare by innovating affordable healthcare solutions for all. The dawn of the present century was marked by the physical and functional classification of nucleic acid sequence information that make up all the genes of the human genome. The 21st century healthcare will be inevitably influenced by our understanding of the these sequences and their complex expression patterns and structural variations that underpin evolution of tumors. The current focus of Diagnostring Laboratories is to build the largest portfolio of AI/ML-driven genomic tests to predict cancer recurrence in individual's diagnosed with benign tumor. These predictive tests, when available, may help save lives. Please visit our product page to learn more.